alkermes appoints mark stejbach as chief commercial officer  business wire alkermes appoints mark stejbach as chief commercial officer march    am eastern standard time dublinbusiness wirealkermes plc nasdaq alks today announced that mark stejbach has been appointed chief commercial officer in this newly created role mr stejbach will be responsible for alkermes’ commercial activities including marketing and sales of vivitrol® naltrexone for extendedrelease injectable suspension and developing and executing commercial strategies for alkermes’ latestage pipeline assets namely alks 0 for schizophrenia alks  for opioidinduced constipation and alks  for treatmentresistant depression mr stejbach will serve on the executive management team of alkermes “we are very pleased to welcome mark to alkermes as we continue to build our commercial capabilities in preparation for the expansion of our commercial product portfolio” said richard pops chief executive officer of alkermes “we look forward to having mark accelerate and expand our commercial activities for vivitrol as well as provide forwardlooking insight into our latestage pipeline development activities our goal is to build alkermes plc into one of the next great biotechnology companies and a strong commercial capability is a key strategic asset” a seasoned executive with  years of experience in biotech and pharmaceutical marketing sales managed care and finance mr stejbach brings extensive commercial experience to the role of chief commercial officer at alkermes he served most recently as chief commercial officer at tengion inc he previously served as vice president of managed care marketing at merck  co inc from  until  where he was responsible for marketing planning across all public and private payor segments including contracting strategy program development and economic affairs prior to  mr stejbach held several other senior positions at merck where he led marketing campaigns for a number of products including vasotec® and proscar® and at biogen idec inc where he was responsible for the development and execution of the launch marketing plan for avonex® mr stejbach received his mba from the wharton school university of pennsylvania and a bs in mathematics from virginia tech “i am thrilled to join alkermes at this extremely exciting time for the company and i see tremendous potential for vivitrol as well as the robust pipeline of new product candidates” commented mark stejbach “i look forward to enhancing the company’s commercial capabilities to achieve its ultimate goal of bringing unique and compelling medicines to patients in need” about alkermes plc alkermes plc is a fully integrated global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes the company has a diversified portfolio of more than  commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system cns disorders such as addiction schizophrenia and depression headquartered in dublin ireland alkermes plc has an rd center in waltham massachusetts and manufacturing facilities in athlone ireland gainesville georgia and wilmington ohio for more information please visit alkermes’ website at wwwalkermescom note regarding forwardlooking statements certain statements set forth above may constitute forwardlooking statements within the meaning of the private securities litigation reform act of  including but not limited to the potential therapeutic and commercial value of the company’s product candidates and of vivitrol for the treatment of alcohol dependence and the prevention of relapse to opioid dependence following opioid detoxification the expansion of our commercial product portfolio and capabilities and the acceleration and expansion of commercial activities for vivitrol although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations the forwardlooking statements are neither promises nor guarantees the company’s business is subject to significant risk and uncertainties and there can be no assurance that its actual results will not differ materially from its expectations these risks and uncertainties include among others whether the therapeutic results demonstrated in clinical studies of our product candidates and vivitrol will be predictive of future therapeutic results in clinical studies and in realworld use of the product whether thirdparty payors will cover or reimburse vivitrol for the prevention of relapse to opioid dependence following opioid detoxification and those risks described in our registration statement on form s commission file number  which was declared effective by the securities and exchange commission “sec” on august   and in other filings made by the company with the sec which are available at the sec’s website at wwwsecgov the information contained in this press release is provided by the company as of the date hereof and except as required by law the company disclaims any intention or responsibility for updating any forwardlooking information contained in this press release vivitrol® is a registered trademark of alkermes inc vasotec® is a registered trademark of biovail laboratories international proscar® is a registered trademark of merck sharp  dohme corp avonex® is a registered trademark of biogen idec inc contacts alkermesfor investorsrebecca peterson  orfor mediajennifer snyder   contacts alkermesfor investorsrebecca peterson  orfor mediajennifer snyder   search advanced news search advanced news search log in sign up mark stejbach  alkermes  inc  zoominfocom   ﻿ richard pops chairman and ceo of alkermes biotech company  alkermes home contact us site map about us about us about alkermes our company message from the ceo locations leadership management team board of directors collaborations strategic partners products products products products overview united states aristada® vivitrol® us products using alkermes technologies wholesaler and purchasing information european union eu products using alkermes technologies research  development research  development research  development rd overview our rd approach pipeline technology platforms manufacturing other information clinical trials expanded access responsibility responsibility responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors investors investors corporate overview press releases investor events stock information sec filings annual reports financials snapshot trading statistics other information email alerts news  events news  events news  events press releases media kit careers careers careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer job opportunities jobs overview field sales roles all available roles about us home about us management team about alkermes our company message from the ceo locations leadership management team board of directors collaborations strategic partners management team richard pops serves as chairman and chief executive officer of alkermes he joined alkermes as ceo in  under his leadership alkermes has grown from a privately held company with  employees to an international publicly traded biopharmaceutical company with more than  employees alkermes has a diversified commercial product portfolio and a substantial clinical pipeline of central nervous system cns product candidates mr pops currently serves on the board of directors of neurocrine biosciences acceleron pharma epizyme the biotechnology industry organization bio the pharmaceutical research and manufacturers of america phrma and the national health council shane cooke oversees corporate finance commercial business development corporate planning quality and manufacturing operations mr cooke joined alkermes as president upon completion of the merger between elan drug technologies edt and alkermes inc in september  previously mr cooke was head of edt and executive vice president of elan from  through the merger in  and concurrently served as chief financial officer of elan corporation from  to may  mr cooke was appointed director of elan in may  prior to joining elan mr cooke was chief executive of pembroke capital limited an aviation leasing company of which he was a founder mr cooke also previously held a number of senior positions in finance in the banking and aviation industries mr cooke currently serves on the board of directors of endo international plc and on the board of directors of prothena biosciences and prothena therapeutics both subsidiaries of prothena corporation plc mr cooke is a chartered accountant and a graduate of university college dublin ireland kathy biberstein oversees compliance intellectual property legal policy information technology human resources and operations at the waltham site she also has responsibility for enterprise risk management ms biberstein held several senior legal positions prior to joining alkermes in  including general counsel and member of the executive committee at serono in geneva switzerland from  to  where she built a worldwide legal department just prior to joining alkermes ms biberstein was of counsel at crowell  moring llc and earlier in her career ms biberstein was a member of the executive board of the world economic forum ms biberstein received a bachelor of science degree from kettering university and a juris doctor from the university of michigan law school iain brown is responsible for alkermes’ accounting and financial reporting systems as well as its tax treasury financial planning and analysis and insurance functions mr brown has more than  years of experience in the biopharmaceutical industry he joined alkermes in  prior to which he managed emd serono’s north america financial operations mr brown received a bachelor of science in business studies from the university of bradford england and is a chartered accountant madeline coffin leads alkermes’ human resources team with responsibility for global compensation and benefits talent acquisition employee engagement and growth and organization development ms coffin has held a number of senior human resource positions at companies including analog devices sun microsystems wang software and bay networks prior to joining alkermes she founded her own company which focused on the strategic human resource needs of growing companies for clients in a broad range of industries ms coffin holds a bachelor of arts degree from penn state university and a master of industrial and labor relations from cornell university elliot ehrich leads the discovery delivery science research and development project management and medical affairs functions at alkermes prior to joining alkermes in  dr ehrich spent seven years at merck  co overseeing the successful clinical development and registration of novel pharmaceuticals dr ehrich is a fellow of the american college of rheumatology and has had numerous publications in peerreviewed journals he also serves on the scientific advisory boards of aileron therapeutics and heptares therapeutics both privately held biopharmaceutical companies as well as a strategic advisor at verge genomics dr ehrich was a phi beta kappa graduate of princeton university where he received a bachelor of arts degree in biochemistry he worked as a research associate at the european molecular biology laboratory embl in heidelberg germany and later earned his medical degree from columbia university college of physicians and surgeons at stanford university dr ehrich completed a residency in internal medicine and a clinical fellowship in the department of immunology and rheumatology he was subsequently a postdoctoral research fellow at the howard hughes medical institute at stanford university school of medicine in the department of microbiology and immunology jim frates serves as chief financial officer of alkermes prior to joining alkermes in  mr frates was a vice president in charge of the east coast life sciences practice at robertson stephens  company he also worked in healthcare investment banking at morgan stanley  company and spent a year teaching secondary school at the royal shrewsbury school in the uk as the harvard college fellow mr frates served on the board of directors of gpc biotech ag from june  to june  and was a national director of the association of bioscience financial officers mr frates serves on the board of directors of sage therapeutics and as a trustee of the roxbury latin school mr frates received a bachelor of arts degree in government from harvard college and a master of business administration from harvard graduate school of business administration david gaffin serves as alkermes’ inhouse chief legal officer managing the operations of the legal department mr gaffin was most recently the us general counsel of alkermes prior to joining the company in  mr gaffin held the role of assistant general counsel at biogen inc where he provided legal counsel on productrelated matters and negotiated collaboration and licensing transactions mr gaffin received a bachelor of arts degree from harvard college a master of business administration from jl kellogg graduate school of management and a juris doctor from northwestern university school of law georgianna harris leads the regulatory affairs department at alkermes in this role dr harris provides regulatory strategy and guidance for development candidates and commercial products prior to joining alkermes dr harris spent  years at merck in positions of increasing responsibility spanning laboratory research and regulatory affairs during her tenure with merck’s regulatory affairs organization dr harris oversaw global development registration and postregistration activities for multiple smallmolecule and biologic medicines for obesity bone oncology diabetes and women’s health indications dr harris received a bachelor of science degree from boston college and a phd in biochemistry from the university of wisconsin she was subsequently a postdoctoral research fellow at the massachusetts institute of technology in the department of chemistry craig hopkinson md is responsible for evolving and executing the clinical development programs for the company’s pipeline of drug candidates dr hopkinson has more than  years of experience building and leading clinical development organizations and medical affairs groups in the biopharmaceutical industry he has led multidisciplinary development teams in multiple therapeutic areas including neuroscience oncology gastroenterology infectious diseases cardiovascular conditions inflammation genetic diseases hematology and neurodegenerative diseases and has extensive knowledge of clinical study design and the regulatory landscape most recently dr hopkinson held the position of senior vice president and head of global medical affairs for vertex pharmaceuticals prior to this role dr hopkinson held various executive management positions at eisai pharmaceuticals including president of eisai value maximization systems president and chief medical officer of the frontier product creation unit and vice president of medical affairs oncology in addition dr hopkinson served in leadership positions at elan pharmaceuticals actelion pharmaceuticals and pfizer dr hopkinson completed his bachelor of medicine and bachelor of surgery at the university of the orange free state in south africa blair jackson leads business development at alkermes encompassing licensing efforts new product evaluation and alliance management since joining alkermes in  mr jackson has served in various roles within the company in both a scientific and corporate capacity mr jackson serves on the board of directors of reset therapeutics inc mr jackson received a bachelor of arts degree in biochemistry from the university of calgary a bachelor of arts in chemical engineering and a master of business administration from the university of alberta and a master of science in chemical engineering practice from the massachusetts institute of technology mike landine oversees alkermes’ corporate development activities prior to leading corporate development mr landine served as chief financial officer and treasurer of alkermes from march  until june  mr landine is a member of the board of directors of kopin corporation a publicly traded manufacturer of components for electronic products he also previously served on the board of directors of gtc biotherapeutics a biotechnology company from  to 0 mr landine received a bachelor of science degree in accounting from bentley university and is a certified public accountant mark namchuk leads research pharmaceutical development process development and nonclinical development of the company’s earlystage product pipeline at alkermes prior to joining alkermes in  dr namchuk served as senior vice president and interim global head of research for vertex pharmaceuticals leading a group of more than 0 researchers in the discovery of transformational medicines in the areas of infectious disease oncology inflammatory diseases neurology and cystic fibrosis in addition dr namchuk developed the high throughput enzymology paradigm in support of the vertex chemogenomics effort and cochaired the committee responsible for newtarget selection and prosecution for the company earlier in his career he served as the head of the biochemistry group at cubist pharmaceuticals dr namchuk obtained his doctorate in bioorganic chemistry from the university of british columbia and completed a postdoctoral fellowship at the university of california san francisco peter norman leads the us government affairs and policy function for the company which includes federal and state initiatives as well as programs with professional and patient organizations prior to joining alkermes in  mr norman was the head of the washington dc office for eisai inc in addition he’s held senior positions for amylin pharmaceuticals inc millennium pharmaceuticals inc novo nordisk and the biotechnology industry organization bio mr norman worked on public policy and regulatory strategies not only for alzheimer’s disease obesity and diabetes pharmaceutical products but also healthcare reform and reimbursement issues he received a bachelor of arts degree from adrian college and a juris doctor from the university of toledo college of law declan o’connor is responsible for alkermes’ manufacturing operations at the athlone ireland and wilmington ohio sites as well as its commercial and clinical supply chain functions mr o’connor is responsible for the strategic development of operations activities and site infrastructure development he joined alkermes as vice president and general manager in athlone upon completion of the merger between elan drug technologies edt and alkermes inc in september  in this role he was responsible for the company’s fdaema licensed multiproduct development manufacturing and packaging operations in ireland mr o’connor held a number of senior operations positions for elan including vice president of finance head of global supply chain and head of finance us operations mr o’connor is a chartered accountant and a graduate of university college dublin ireland phil shanahan is responsible for quality control quality assurance and compliance at the athlone ireland and wilmington ohio sites and the quality assurance function at the waltham site dr shanahan joined alkermes as vice president quality operations upon completion of the merger between elan drug technologies edt and alkermes inc in september  dr shanahan has more than  years of experience in quality operations prior to joining elan he served at servier and janssen global services llc dr shanahan obtained his doctorate in analytical biotechnology and his bachelor of science in chemistry from university college cork he holds a diploma in pharmaceutical manufacturing technology and is a certified qualified person qp for the release of product to the european union mark stejbach serves as chief commercial officer at alkermes and is responsible for all aspects of alkermes’ commercial functions including sales marketing managed care and trade channels commercial analytics public policy and the development of commercial strategy for the company’s proprietary pipeline mr stejbach has more than  years of experience in biotech and pharmaceutical marketing sales managed care and finance prior to joining alkermes mr stejbach served at tengion inc from  to  most recently as chief commercial officer he previously held senior positions at merck  co and biogen idec inc he currently serves on the board of directors of flexion therapeutics mr stejbach received his mba from the wharton school university of pennsylvania and a bachelor of science in mathematics from virginia tech richard f pops shanecooke kathryn l biberstein iainbrown madeline d coffin elliot w ehrich md james m frates david jgaffin georgianna harris phd craig hopkinson md blair c jackson michael j landine mark namchuk phd peternorman declan o’connor phil shanahan phd mark p stejbach you are now leaving alkermescom about us our company message from the ceo locations management team board of directors strategic partners products products overview aristada® vivitrol® us products using alkermes technologies eu products using alkermes technologies wholesaler and purchasing information research  development rd overview our rd approach pipeline technology platforms manufacturing clinical trials expanded access responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors corporate overview press releases investor events stock information sec filings annual reports snapshot trading statistics email alerts news  events press releases media kit careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer jobs overview field sales roles all available roles  alkermes all rights reserved terms of use privacy policy mark p stejbach  senior vice president  chief commercial officer at alkermes plc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink mark p stejbach senior vice president  chief commercial officer at alkermes plc overview in the news relationships paths education career history boards  committees public holdings transactions mark p stejbach senior vice president  chief commercial officer at alkermes plc overview age  born  board seats  number of relationships this person is connected to  people in the news see more globenewswire march   flexion reports yearend  financial results globenewswire november   flexion therapeutics reports third quarter  financial results globenewswire september   flexion therapeutics announces appointment of mark stejbach to its board of directors relationships see details richard pops chief executive officer at alkermes plc mike clayman former chief executive officer  cofounder at flexion therapeutics inc michael j landine director at alkermes inc samuel d colella cofounder at versant venture management llc scott a canute former president global manufacturing operations at eli lilly  company alan w milinazzo partner at heidrick  struggles international inc patrick j mahaffy cofounder at clovis oncology inc heath lukatch partner  managing director at tpg biotech sandesh mahatme executive vice president chief financial officer  chief business officer at sarepta therapeutics inc ann merrifield treasurer  director at ymca of greater boston inc see 0 more listings with relsci professional start my free trial ➤ see 0 more paths to mark p stejbach mark p stejbach you connections via relationship science mark p stejbach sync your contacts to see how you can connect with mark p stejbach start my free trial ➤ see more educational background bachelor of science mathematics  virginia polytechnic institute and state university virginia tech takes a handson engaging approach to education preparing scholars to be leaders in their fields and communities as the commonwealth’s most comprehensive university and its leading research institution virginia tech offers  undergraduate and graduate degree programs to more than 0 students and manages a research portfolio of more than 0 million the university fulfills its landgrant mission of transforming knowledge to practice through technological leadership and by fueling economic growth and job creation locally regionally and across virginia master of business administration  university of pennsylvania  the wharton school the wharton school is the business school of the university of pennsylvania an ivy league university in philadelphia pennsylvania wharton was the world’s first collegiate business school and the first business school in the united states it was established in  through a donation of joseph wharton career history senior vice president  chief commercial officer   current alkermes plc alkermes is a leader in innovative medicines that address the unmet needs and challenges of people living with debilitating diseases as a fully integrated global biopharmaceutical company alkermes applies our scientific expertise proprietary technologies and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease chief commercial officer    tengion inc tengion inc is a regenerative medicine company focused on discovering developing manufacturing and commercializing of neoorgans and products tengion was founded by steven nichtberger and david i scheer on july 0  and is headquartered in winstonsalem nc professional    biogen ma inc biogen ma inc is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering the company’s research and development activities used to focus on novel products for multiple sclerosis inflammatory respiratory kidney and cardiovascular diseases developmental biology and gene therapy the company was founded by daniel d adams in  and is headquartered in cambridge ma vice presidentmanaged care marketing prior merck  co inc merck  co inc  dba merck sharp  dohme msd outside the united states and canada is an american pharmaceutical company and is one of the largest pharmaceutical companies in the world professional prior biogen inc biogen inc is a global biotechnology company which focuses on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders its products include avonex plegridy tecfidera tysabri and fampyra for multiple sclerosis alprolix for hemophilia b and eloctate for hemophilia a the company also collaborates on the development and commercialization of rituxan for the treatment of nonhodgkins lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for gazyva which is approved for the treatment of chronic lymphocytic leukemia biogen was founded by phillip allen sharp in  and is headquartered in cambridge ma boards  committees corporate boards ▾ independent director   current flexion therapeutics inc flexion therapeutics inc is a pharmaceutical company which focuses on the development and commercialization of novel local therapies the firm specializes in treatment of patients with musculoskeletal conditions including osteoarthritis it offers products under the zilretta brand the company was founded by michael d clayman and neil bodick on november   and is headquartered in burlington ma nonprofit boards ▾ member advisory board   current university of michigan  center for valuebased insurance design public holdings restricted data only for relsci professional users start my free trial ➤ see more transactions details hidden tengion inc raised money in a private placement transaction other affiliations mark p stejbach is affiliated with alkermes plc tengion inc biogen ma inc merck  co inc biogen inc flexion therapeutics inc university of michigan  center for valuebased insurance design youve reached your 0 free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext0 about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows 0 click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft flexion therapeutics announces appointment of mark stejbach to its board of directors  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules0 trading commandments real money access rm rules of investingjim cramers best stocks for 0 commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under 0 top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street flexion therapeutics announces appointment of mark stejbach to its board of directors globenewswire sep    am edt burlington mass sept   globe newswire  flexion therapeutics inc nasdaqflxn announced today the appointment of mark stejbach senior vice president and chief commercial officer at alkermes plc to its board of directors as the company prepares for commercialization of its drug candidate zilretta™ also known as fx a potential treatment for patients with moderate to severe knee osteoarthritis oa pain flexion plans to submit a new drug application nda in the fourth quarter of  to the us food and drug administration fda michael clayman md president and chief executive officer of flexion stated we are delighted to be bringing marks considerable commercial experience and knowhow to our board of directors we are confident that his strategic expertise and his deep and current knowledge of sales and marketing will complement the backgrounds of the existing board members and will contribute insight and perspective to our recently expanded internal commercial capabilities all of this is vitally important as we prepare zilretta for potential approval and commercial launch which we anticipate to happen in  mr stejbach has more than  years of leadership experience in biotech and commercial marketing sales managed care and finance as chief commercial officer at alkermes mr stejbach is responsible for marketing sales managed care and trade channels commercial analytics patient services new product planning and commercial strategy previously he served at tengion inc from  to  most recently as chief commercial officer he previously held senior positions at merck  co and biogen idec mr stejbach received his mba from the university of pennsylvania and a bachelor of science in mathematics from virginia tech im honored to join the flexion therapeutics board of directors as the company prepares to submit an nda for its drug candidate zilretta to the fda said mr stejbach if approved for commercialization zilretta would be an important drug in the armamentarium of physicians who treat patients with pain associated with knee oa if you liked this article you might like biotech movers ocular alder flexion ocular therapeutix alder biopharmaceuticals flexion therapeutics were among the biotech stock movers in premarket trading on july  armie margaret lee jul    am edt  recovering biotech names with room to run there are reasons to believe rallies in biodelivery sciences and flexion therapeutics should continue bret jensen jun    am edt biotech movers coherus xbiotech flexion coherus biosciences xbiotech and flexion therapeutics were among the biotech stock movers in premarket trading on monday armie margaret lee jun    am edt  undervalued biotech stocks two are turnaround stories and two are oversold bret jensen jun   0 am edt trending jim cramer nails starbucks big decline warns again of downside to 0 how amazon billionaire jeff bezos gained vast riches and a tech giant someday worth  trillion starbucks shares are plunging by more than 0  go out and buy worst performing tech stocks amzn amd mu wdc teslas model  arrives on friday  heres everything you need to know about this overhyped ride advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers alkermes appoints mark stejbach as chief commercial officer  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules0 trading commandments real money access rm rules of investingjim cramers best stocks for 0 commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under 0 top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street alkermes appoints mark stejbach as chief commercial officer business wire mar    am est alkermes plc nasdaq alks today announced that mark stejbach has been appointed chief commercial officer in this newly created role mr stejbach will be responsible for alkermes’ commercial activities including marketing and sales of vivitrol® naltrexone for extendedrelease injectable suspension and developing and executing commercial strategies for alkermes’ latestage pipeline assets namely alks 0 for schizophrenia alks  for opioidinduced constipation and alks  for treatmentresistant depression mr stejbach will serve on the executive management team of alkermes “we are very pleased to welcome mark to alkermes as we continue to build our commercial capabilities in preparation for the expansion of our commercial product portfolio” said richard pops chief executive officer of alkermes “we look forward to having mark accelerate and expand our commercial activities for vivitrol as well as provide forwardlooking insight into our latestage pipeline development activities our goal is to build alkermes plc into one of the next great biotechnology companies and a strong commercial capability is a key strategic asset” a seasoned executive with  years of experience in biotech and pharmaceutical marketing sales managed care and finance mr stejbach brings extensive commercial experience to the role of chief commercial officer at alkermes he served most recently as chief commercial officer at tengion inc he previously served as vice president of managed care marketing at merck  co inc from  until  where he was responsible for marketing planning across all public and private payor segments including contracting strategy program development and economic affairs prior to  mr stejbach held several other senior positions at merck where he led marketing campaigns for a number of products including vasotec ® and proscar ® and at biogen idec inc where he was responsible for the development and execution of the launch marketing plan for avonex ® mr stejbach received his mba from the wharton school university of pennsylvania and a bs in mathematics from virginia tech “i am thrilled to join alkermes at this extremely exciting time for the company and i see tremendous potential for vivitrol as well as the robust pipeline of new product candidates” commented mark stejbach “i look forward to enhancing the company’s commercial capabilities to achieve its ultimate goal of bringing unique and compelling medicines to patients in need” if you liked this article you might like  drug companies that are helping to solve the opioid crisis that goldman sachs just shed light on the top names breana noble jul    pm edt making sense of thursdays flood of biotech and pharma earnings reports a guide to keep track of all the companies reporting first quarter financial results today  making sense of whats important and disregarding whats not adam feuerstein apr    pm edt making sense of thursdays flood of biotech and pharma earnings reports a guide to keep track of all the companies reporting first quarter financial results today  making sense of whats important and disregarding whats not thestreet staff apr   0 am edt verizon randgold resources bank of america mad money lightning round jim cramer is bullish on nektar therapeutics and alkermes as well as verizon and bank of america bret kenwell apr    am edt trending how amazon billionaire jeff bezos gained vast riches and a tech giant someday worth  trillion jim cramer nails starbucks big decline warns again of downside to 0 starbucks shares are plunging by more than 0  go out and buy worst performing tech stocks amzn amd mu wdc teslas model  arrives on friday  heres everything you need to know about this overhyped ride advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers mark stejbach merck  pharmaceutical executive log inregister search this site this site include affiliate sites magazinecurrent issue digital edition issues archive topicsfrom the editor new and noteworthy strategy regulatory washington report sales  marketing europe global rd events resourceswebcasts podcasts videos whitepapers ebooks front  center sponsored blogs subscribe advertise contact us europe from the editor global new  noteworthy rd sales  marketing strategy   most read current issue top features new  noteworthy washington report webcasts share printerfriendly version send by email mark stejbach merck jun 0  by pharmaceutical executive editors pharmaceutical executive mark stejbach vp managed care marketing merck double duty is helping build mercks new healthcare model of note first nonfinance person to run mercks investor relations on payers mark stejbach for many years the success of the industry was at least in part driven by the inefficiency of the economic model of healthcare in the short term theres always more to be eked out from the current model—and i think some companies are going to run with that as hard and as long as they can but in the long term companies have to understand that the market is going to be increasingly influenced by the people who pay the bills—payers and consumers in that way pharma will start to become more like most other industries nativex subscribe printdigital productslinkedin  twitter podcastswebcastsrss feed     compliance top of mind there is never a lack of legal or regulatory issues to keep track of—and worry about—in the life sciences industry the articles from pharmaceutical executive provide a look at the latest in compliance for marketing labeling and export control as well as offer tips to stay compliant in the coming years read more sponsored links contact us home advertise current issue subscribe enews subscribe twitter cbi conferences linkedin rss linking and rss policy privacy policy terms of use reprints applied clinical trials biopharm international lcgc  chromacademy nutritional outlook pharmaceutical technology spectroscopy   ubm all rights reserved lorem ipsum mark stejbach joins alkermes  drug store news open search form log in  create an account toggle navigation linkedin facebook twitter rss continuing pharmacy education dsn drugstorenews mark stejbach joins alkermes march    by allison cerra ‌​ dublin — alkermes has appointed a new chief commercial officer mark stejbach who brings  years of experience in biotech and pharmaceutical marketing sales managed care and finance to his new role will be responsible for alkermes commercial activities including marketing and sales of vivitrol and developing and executing commercial strategies for alkermes latestage pipeline assets namely alks 0 for schizophrenia alks  for opioidinduced constipation and alks  for treatmentresistant depression prior to joining the company stejbach served as chief commercial officer for tengion a leader in regenerative medicine “we are very pleased to welcome mark to alkermes as we continue to build our commercial capabilities in preparation for the expansion of our commercial product portfolio” alkermes ceo richard pops said “we look forward to having mark accelerate and expand our commercial activities for vivitrol as well as provide forwardlooking insight into our latestage pipeline development activities our goal is to build alkermes plc into one of the next great biotechnology companies and a strong commercial capability is a key strategic asset” interested in this topic sign up for our weekly collaborative care enewsletter login or register to post a comment ﻿ newsletter sign up get the latest news sent to your inbox   popular most commented estée lauder launches second capsule collection with victoria beckham ncpa innovation center announces mental health first aid training scholarship winners teva intros generic epiduo in the us changing consumer desires have slowed color cosmetics growth in  nacds applauds decision to not pursue border adjustment tax study consumer demand for personal care ingredient information is on the rise fda approves acella’s generic vituz oral solution envoyhealth and cmt pilot patient medication adherence program bat dropped from tax reform effort teva intros generic epiduo in the us poll poll the house gop has passed a bill to replace the aca what business do you think the ahca will help most if it passes the senate pharmacy utilization otc retail clinics special reports special report super bugs a new breed of drugresistant head lice is driving a new wave of product solutions dsn senior editor michael johnsen takes a deeper look at what retailers and suppliers are doing to combat super bugs in this special report read more   in this issue july  drug store news highlights parents and suppliers search for new solutions to the super bug problem takes a closer look at retail clinics and what five top chains are doing to stand out in the space recaps whats new and trending in the skin sun and bath care categories and more read more new products fda approves acella’s generic vituz oral solution the combination medicine is indicated for the relief of cough and symptoms estée lauder launches second capsule collection with victoria beckham beckham will front the digital and print campaign with imagery shot by elizabeth arden tapout partner on body spray line the sixproduct line of body sprays come in a range of scents that range from coffee booster wins ecrmdrug store news buyers choice award corrjensen was a finalist with its orb sleep complex vitamins